[logo] HealthTree Foundation
search person

How Long Will I Live With Enteropathy-Associated Intestinal T-Cell Lymphoma?

The prognosis for enteropathy-associated intestinal T-cell lymphoma (EATL) varies greatly depending on several factors, including the stage of the disease at diagnosis, the patient's overall health, and the response to treatment. It's important to note that statistics can provide a general idea, but they cannot predict the exact prognosis for an individual patient.

What Do Statistics Say About the Life Expectancy for Someone with Enteropathy-Associated Intestinal T-Cell Lymphoma?

Due to the rarity of EATL, comprehensive survival statistics are limited. However, studies suggest that the overall survival rate is generally low, although long term survival is a possibility, including those who are cured of the disease. A study published in the Journal of Clinical Oncology reported a median survival of less than a year for patients with EATL. Another source reports that 5-year survival varies from 8 to 60% depending on the patient's ability to receive additional types of therapy. Survival rates have been improving with advances in treatment. The most favorable outcomes are in people who recieve an autologous stem cell trasnplant, but many people are not candidates due to the state of their health at the time of diagnosis. It's crucial to remember that these are median values, and an individual's prognosis can vary widely.

What Factors Affect Prognosis for Enteropathy-Associated Intestinal T-Cell Lymphoma?

  • Stage of the disease: Patients diagnosed at an early stage generally have a better prognosis than those diagnosed at a later stage.
  • Overall health: Patients who are otherwise healthy may have a better prognosis than those with other health conditions.
  • Response to treatment: Patients who respond well to treatment often have a better prognosis.
  • Age: Younger patients generally have a better prognosis than older patients.
  • Performance status: This refers to the patient's ability to perform everyday activities. Patients with a good performance status generally have a better prognosis.

It's important to note that survival statistics are general trends and a patient's individual prognosis can vary greatly. Each patient's case is unique and should be discussed with their healthcare provider. Having an EATL specialist on your team provides you with the best way of truly understanding your prognosis. Visit HealthTree's EATL Specialist Directory to find an EATL expert near you. You can also join HealthTree's social media platform, HealthTree Connect to meet other EATL patients and learn what they've done personally to live longer with EATL. 

Want to Learn More About Enteropathy-Associated Intestinal T-Cell Lymphoma?

Keep reading HealthTree for Enteropathy-Associated Intestinal T-Cell Lymphoma's 101 pages!

The prognosis for enteropathy-associated intestinal T-cell lymphoma (EATL) varies greatly depending on several factors, including the stage of the disease at diagnosis, the patient's overall health, and the response to treatment. It's important to note that statistics can provide a general idea, but they cannot predict the exact prognosis for an individual patient.

What Do Statistics Say About the Life Expectancy for Someone with Enteropathy-Associated Intestinal T-Cell Lymphoma?

Due to the rarity of EATL, comprehensive survival statistics are limited. However, studies suggest that the overall survival rate is generally low, although long term survival is a possibility, including those who are cured of the disease. A study published in the Journal of Clinical Oncology reported a median survival of less than a year for patients with EATL. Another source reports that 5-year survival varies from 8 to 60% depending on the patient's ability to receive additional types of therapy. Survival rates have been improving with advances in treatment. The most favorable outcomes are in people who recieve an autologous stem cell trasnplant, but many people are not candidates due to the state of their health at the time of diagnosis. It's crucial to remember that these are median values, and an individual's prognosis can vary widely.

What Factors Affect Prognosis for Enteropathy-Associated Intestinal T-Cell Lymphoma?

  • Stage of the disease: Patients diagnosed at an early stage generally have a better prognosis than those diagnosed at a later stage.
  • Overall health: Patients who are otherwise healthy may have a better prognosis than those with other health conditions.
  • Response to treatment: Patients who respond well to treatment often have a better prognosis.
  • Age: Younger patients generally have a better prognosis than older patients.
  • Performance status: This refers to the patient's ability to perform everyday activities. Patients with a good performance status generally have a better prognosis.

It's important to note that survival statistics are general trends and a patient's individual prognosis can vary greatly. Each patient's case is unique and should be discussed with their healthcare provider. Having an EATL specialist on your team provides you with the best way of truly understanding your prognosis. Visit HealthTree's EATL Specialist Directory to find an EATL expert near you. You can also join HealthTree's social media platform, HealthTree Connect to meet other EATL patients and learn what they've done personally to live longer with EATL. 

Want to Learn More About Enteropathy-Associated Intestinal T-Cell Lymphoma?

Keep reading HealthTree for Enteropathy-Associated Intestinal T-Cell Lymphoma's 101 pages!

newsletter icon

Get the latest thought leadership on your Enteropathy-Associated Intestinal T-Cell Lymphoma delivered straight to your inbox

Subscribe to the weekly newsletter for news, stories, clinical trial updates, and helpful resources and events with cancer experts.

Thanks to our HealthTree Community for Enteropathy-Associated Intestinal T-Cell Lymphoma Sponsors:

Abbvie
Astellas Pharma
Servier